Immunovant, Inc.
IMVT
$15.08
$0.191.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -447.30M | -413.84M | -382.71M | -323.01M | -272.55M |
| Total Depreciation and Amortization | 404.00K | 377.00K | 332.00K | 291.00K | 258.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 54.63M | 49.62M | 47.84M | 46.68M | 44.79M |
| Change in Net Operating Assets | -24.82M | -12.03M | 9.60M | 4.39M | -15.55M |
| Cash from Operations | -417.09M | -375.87M | -324.94M | -271.64M | -243.06M |
| Capital Expenditure | -577.00K | -759.00K | -708.00K | -659.00K | -497.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -577.00K | -759.00K | -708.00K | -659.00K | -497.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 457.04M | 454.81M | 5.43M | 478.82M | 478.24M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -319.00K | -319.00K | 0.00 | -6.01M | -6.01M |
| Cash from Financing | 456.72M | 454.49M | 5.43M | 472.81M | 472.22M |
| Foreign Exchange rate Adjustments | -154.00K | 747.00K | 3.97M | 2.51M | 1.38M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 38.91M | 78.61M | -316.25M | 203.01M | 230.05M |